Linagliptin/Metformin Hcl
Brand name: Jentadueto
Rank #388 of 500 drugs by total cost
$24.3M
Total Cost
33,018
Total Claims
$24.3M
Total Cost
1,406
Prescribers
$737
Cost per Claim
1,914
Beneficiaries
47,150
30-Day Fills
$17K
Avg Cost/Provider
23
Avg Claims/Provider
About Linagliptin/Metformin Hcl
Linagliptin/Metformin Hcl (sold as Jentadueto) was prescribed 33,018 times by 1,406 Medicare Part D providers in 2023, costing the program $24.3M. At $737 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 385 | Fremanezumab-Vfrm (Ajovy Autoinjector) | $24.7M | 29,389 |
| 386 | Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro) | $24.4M | 1,173,249 |
| 387 | Pegfilgrastim (Neulasta) | $24.4M | 3,096 |
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
| 389 | Ocrelizumab (Ocrevus) | $24.2M | 639 |
| 390 | Fenofibrate (Fenofibrate) | $24.2M | 670,936 |
| 391 | Empaglifloz/Linaglip/Metformin (Trijardy Xr) | $23.9M | 28,001 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology